Anticancer Research Journal Publishes Groundbreaking Ivermectin
The Anticancer Research Journal is a major international oncology journal of the International Institute of Anticancer Research - established in 1995.
Recently, The Wellness Company announced that a first-of-its-kind human observational study of the off-label use of Ivermectin and Mebendazole in the treatment of cancer was published by the Anticancer Research Journal.
https://armedforces.press/history/2026/06/05/anticancer-research-journal-publishes-groundbreaking-ivermectin/
Dr. Peter McCullough, Chief Scientific Officer for The Wellness Company, and one of the authors of the manuscript, praised the results of this groundbreaking analysis. “In this first-of-its-kind human observational analysis, off-label use of Ivermectin+Mebendazole showed a remarkable 84% Clinical Benefit Ratio in the treatment of cancer. These results indicate that the inexpensive and safe off-label applications of these medications could be an important breakthrough in the treatment of cancer.”
The Anticancer Research Journal is a major international oncology journal of the International Institute of Anticancer Research, established in 1995.
Nicolas Hulscher, of the McCullough Foundation, emphasized just how groundbreaking this type of study is: “Real-world observational studies are incredibly important because they most accurately reflect how Ivermectin+Mebendazole are used in practical applications.”
The publication of this study makes it the largest peer-reviewed human study on the use of Ivermectin + Mebendazole in the treatment of cancer.
84% of Cancer Patients Reported a Clinical Benefit
In this human observational analysis, off-label use of Ivermectin+Mebendazole showed a remarkable 84% Clinical Benefit Ratio in the treatment of cancer. These results indicate that the inexpensive and safe off-label applications of these medications could represent an important breakthrough in cancer treatment.
The report analyzed 197 cancer patients who were prescribed ivermectin and mebendazole off-label. Participants received compounded oral capsules containing 25 mg of ivermectin and 250 mg of mebendazole. After 6-months, participants reported an 84% Clinical Benefit Ratio. With 48% of participants reporting regression or no evidence of cancer, while 36% reported disease stability. Only 15.6% of participants reported disease progression.
Cancer remains one of the leading causes of death globally, with conventional treatments such as chemotherapy, radiation therapy, and targeted agents frequently limited by significant toxicity, high cost, development of resistance, and variable long-term efficacy.
The experts at The Wellness Company undertook this study because ivermectin and mebendazole have demonstrated highly promising anti-cancer activity in preclinical models. Despite compelling preclinical data and documented safety in cancer patients, robust clinical evidence evaluating the ivermectin–mebendazole combination in oncology remains limited.
According to Dr. McCullough, “This study reveals an exciting new potential that should expand the consideration of ivermectin and mebendazole for inclusion in the treatment of multiple cancer types. We urgently need a full-fledged scientific investigation into this class of medications and their impact on cancer treatment.”
Follow this link for more information.